DWDavid Walder

David Walder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Walder has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Amit Patel

    Affiliation King’s College Hospital NHS Foundation Trust, London, United Kingdom

    2 shared publications
  • Amadea Heitmann

    Department of Respiratory Medicine, King's College Hospital NHS Foundation Trust, London, UK

    1 shared publication
  • Andy I. Rutherford

    Affiliation King’s College Hospital NHS Foundation Trust, London, United Kingdom

    1 shared publication
  • Caroline J. Jolley

    Centre for Human and Applied Physiological Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, UK

    1 shared publication
  • Deepak Nagra

    Affiliation Centre for Rheumatic Diseases, King’s College London, London, United Kingdom

    1 shared publication
  • Felicity Perrin

    Department of Respiratory Medicine, King's College Hospital NHS Foundation Trust, London, UK

    1 shared publication

Latest Publications

  • Open Access

    Inpatient COVID-19 mortality has reduced over time: Results from an observational cohort

    by Katie Bechman, Mark Yates, Kirsty Mann, Deepak Nagra, Laura-Jane Smith, Andy I. Rutherford, Amit Patel, Jimstan Periselneris, David Walder, Richard J. B. Dobson, et al.

    Background: The Covid-19 pandemic in the United Kingdom has seen two waves; the first starting in March 2020 and the second in late October 2020. It is not known whether outcomes for those admitted with severe Covid were different in the first and second waves. Methods: The study population comprised all patients admitted to a 1,500-bed London Hospital Trust between March 2020 and March 2021, who tested positive for Covid-19 by PCR within 3-days of admissions. Primary outcome was death within 28-days of admission. Socio-demographics (age, sex, ethnicity), hypertension, diabetes, obesity, baseline physiological observations, CRP, neutrophil, chest x-ray abnormality, remdesivir and dexamethasone were incorporated as co-variates. Proportional subhazards models compared mortality risk between wave 1 and wave 2. Cox-proportional hazard model with propensity score adjustment were used to compare mortality in patients prescribed remdesivir and dexamethasone. Results: There were 3,949 COVID-19 admissions, 3,195 hospital discharges and 733 deaths. There were notable differences in age, ethnicity, comorbidities, and admission disease severity between wave 1 and wave 2. Twenty-eight-day mortality was higher during wave 1 (26.1% versus 13.1%). Mortality risk adjusted for co-variates was significantly lower in wave 2 compared to wave 1 [adjSHR 0.49 (0.37, 0.65) p<0.001]. Analysis of treatment impact did not show statistically different effects of remdesivir [HR 0.84 (95%CI 0.65, 1.08), p = 0.17] or dexamethasone [HR 0.97 (95%CI 0.70, 1.35) p = 0.87]. Conclusion: There has been substantial improvements in COVID-19 mortality in the second wave, even accounting for demographics, comorbidity, and disease severity. Neither dexamethasone nor remdesivir appeared to be key explanatory factors, although there may be unmeasured confounding present.


  • Open Access

    Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia

    by Rebecca F. D'CRuz, Michael D. Waller, Felicity Perrin, Jimstan Periselneris, Sam Norton, Laura-Jane Smith, Tanya Patrick, David Walder, Amadea Heitmann, Kai Lee, et al.

    Background: A standardised approach to assessing COVID-19 survivors has not been established, largely due to the paucity of data on medium- and long-term sequelae. Interval chest radiography is recommended following community-acquired pneumonia; however, its utility in monitoring recovery from COVID-19 pneumonia remains unclear.Methods: This was a prospective single-centre observational cohort study. Patients hospitalised with severe COVID-19 pneumonia (admission duration ≥48 h and oxygen requirement ≥40% or critical care admission) underwent face-to-face assessment at 4–6 weeks post-discharge. The primary outcome was radiological resolution of COVID-19 pneumonitis (Radiographic Assessment of Lung Oedema score −2, 62% male and 70% ethnic minority. Despite radiographic resolution of pulmonary infiltrates in 87%, modified Medical Research Council Dyspnoea (breathlessness) scale grades were above pre-COVID-19 baseline in 44%, and patients reported persistent fatigue (68%), sleep disturbance (57%) and breathlessness (32%). Screening thresholds were breached for post-traumatic stress disorder (25%), anxiety (22%) and depression (18%). 4MGS was slow (−1) in 38% and 35% desaturated by ≥4% during the STS test. Of 56 thoracic computed tomography scans performed, 75% demonstrated COVID-19-related interstitial and/or airways disease.Conclusions: Persistent symptoms, adverse mental health outcomes and physiological impairment are common 2 months after severe COVID-19 pneumonia. Follow-up chest radiography is a poor marker of recovery; therefore, holistic face-to-face assessment is recommended to facilitate early recognition and management of post-COVID-19 sequelae.